Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease
Crossref DOI link: https://doi.org/10.1007/s00296-023-05302-9
Published Online: 2023-03-16
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zekić, Tatjana http://orcid.org/0000-0001-7948-5394
Text and Data Mining valid from 2023-03-16
Version of Record valid from 2023-03-16
Article History
Received: 7 February 2023
Accepted: 1 March 2023
First Online: 16 March 2023